Literature DB >> 12898417

Antimicrobial constituents from goldenseal (the Rhizomes of Hydrastis canadensis) against selected oral pathogens.

Bang Yeon Hwang1, Sara K Roberts, Lucas R Chadwick, Christine D Wu, A Douglas Kinghorn.   

Abstract

Two new C-methyl flavonoids, 6,8-di- C-methylluteolin 7-methyl ether (1) and 6- C-methylluteolin 7-methyl ether (2), were isolated from a commercially available sample of the roots of Hydrastis canadensis, along with seven known compounds, berberine (3), beta-hydrastine (4), canadine (5), canadaline (6), isocorypalmine (7), canadinic acid (8), and beta-sitosterol 3- O-beta- D-glucoside (9). The structures of the new compounds 1 and 2 were elucidated on the basis of their spectral data including 1D and 2D NMR techniques. Of these isolates, berberine (3) and, to a lesser extent, 1 and 2, showed antimicrobial activity when evaluated against the oral pathogens Streptococcus mutans and Fusobacterium nucleatum. Berberine (3) exhibited an additive antimicrobial effect when tested against S. mutans in combination with 1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898417     DOI: 10.1055/s-2003-41115

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  17 in total

1.  Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal (Hydrastis canadensis).

Authors:  Martha Leyte-Lugo; Emily R Britton; Daniel H Foil; Adam R Brown; Daniel A Todd; José Rivera-Chávez; Nicholas H Oberlies; Nadja B Cech
Journal:  Phytochem Lett       Date:  2017-04-15       Impact factor: 1.679

2.  Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis).

Authors:  Hiyas A Junio; Arlene A Sy-Cordero; Keivan A Ettefagh; Johnna T Burns; Kathryn T Micko; Tyler N Graf; Scott J Richter; Robert E Cannon; Nicholas H Oberlies; Nadja B Cech
Journal:  J Nat Prod       Date:  2011-06-10       Impact factor: 4.050

3.  Inhibition of Bacteroidetes and Firmicutes by select phytochemicals.

Authors:  Jourdan E Lakes; Christopher I Richards; Michael D Flythe
Journal:  Anaerobe       Date:  2019-12-24       Impact factor: 3.331

4.  Biochemometrics to Identify Synergists and Additives from Botanical Medicines: A Case Study with Hydrastis canadensis (Goldenseal).

Authors:  Emily R Britton; Joshua J Kellogg; Olav M Kvalheim; Nadja B Cech
Journal:  J Nat Prod       Date:  2017-11-01       Impact factor: 4.050

5.  Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition.

Authors:  Keivan A Ettefagh; Johnna T Burns; Hiyas A Junio; Glenn W Kaatz; Nadja B Cech
Journal:  Planta Med       Date:  2010-12-14       Impact factor: 3.352

6.  Antimicrobial fungal endophytes from the botanical medicine goldenseal (Hydrastis canadensis).

Authors:  Joseph M Egan; Amninder Kaur; Huzefa A Raja; Joshua J Kellogg; Nicholas H Oberlies; Nadja B Cech
Journal:  Phytochem Lett       Date:  2016-08-06       Impact factor: 1.679

Review 7.  Discovery of anti-TB agents that target the cell-division protein FtsZ.

Authors:  Kunal Kumar; Divya Awasthi; William T Berger; Peter J Tonge; Richard A Slayden; Iwao Ojima
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

Review 8.  Grape products and oral health.

Authors:  Christine D Wu
Journal:  J Nutr       Date:  2009-07-29       Impact factor: 4.798

9.  Effects of Dietary Inclusion of Dry Hydrastis canadensis on Laying Performance, Egg Quality, Serum Biochemical Parameters and Cecal Microbiota in Laying Hens.

Authors:  Tzuen-Rong J Tzeng; Tzu-Yu Liu; Chiao-Wei Lin; Pei-En Chang; Pei-Xin Liao; Wen-Yuan Yang; Chih-Yuan Cheng; Pei-Chun Liao; Wen-Dee Chiang; Shih-Torng Ding; Yuan-Yu Lin
Journal:  Animals (Basel)       Date:  2021-05-13       Impact factor: 2.752

10.  Effect of Berberine on PPAR α /NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy.

Authors:  Mingfeng Wang; Jia Wang; Rui Tan; Qin Wu; Hongmei Qiu; Junqing Yang; Qingsong Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.